Meeting
2022 ASCO Annual Meeting
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).
Authors
Ryan Tooker
Tolmar, Inc, Fort Collins, CO
Ryan Tooker , Erika P. Hamilton , Kerlin Lynch , Stuart Atkinson , Ryan Turncliff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04906395
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS608)
DOI
10.1200/JCO.2022.40.16_suppl.TPS608
Abstract #
TPS608
Poster Bd #
378b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients.
First Author: Daniella Audi Blotta
Poster
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2021 ASCO Annual Meeting
Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).
First Author: Fionnuala Crowley